Provided by Tiger Fintech (Singapore) Pte. Ltd.

Moleculin Biotech

0.6651
+0.03715.91%
Post-market: 0.6560-0.0091-1.37%19:49 EDT
Volume:2.15M
Turnover:1.39M
Market Cap:20.09M
PE:-0.15
High:0.6899
Open:0.6000
Low:0.5920
Close:0.6280
Loading ...

Moleculin Biotech Inc. Receives Positive FDA Feedback for Pediatric Study Plan of Annamycin in Children with R/R AML

Reuters
·
18 Jun

Moleculin Biotech announces ‘What This Means’ virtual investor segment

TIPRANKS
·
11 Jun

Moleculin Biotech Coverage Assumed by HC Wainwright & Co. at Buy

Dow Jones
·
09 Jun

Moleculin Biotech: Positive Clinical Trial Results and Strategic Developments Support Buy Rating

TIPRANKS
·
06 Jun

Moleculin Biotech Hosts Key Opinion Leaders Event

TIPRANKS
·
05 Jun

Moleculin Biotech releases KOL webcast to discuss Phase 1B/2 annamycin data

TIPRANKS
·
05 Jun

Moleculin Biotech Shares Slump After Phase 1b/2 Trial of Annamycin Fails to Show Complete Responses

MT Newswires Live
·
05 Jun

Moleculin Biotech Stock (MBRX) Dives 10% on Clinical Trial Results

TIPRANKS
·
04 Jun

Moleculin Biotech files to sell 10.99M shares of common stock, warrants

TIPRANKS
·
03 Jun

Moleculin Biotech Faces Nasdaq Non-Compliance Notice

TIPRANKS
·
24 May

Moleculin Biotech Inc. Faces Nasdaq Listing Rule Violation, Granted 45 Days to Submit Compliance Plan

Reuters
·
24 May

Moleculin Biotech’s Growth Potential Highlighted by Phase 3 MIRACLE Trial and Strategic Advancements

TIPRANKS
·
15 May

Moleculin Biotech Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
14 May

Moleculin Biotech Reports Q1 2025 Financials: R&D Expenses Decrease by $0.9M, G&A Expenses Slightly Increase

Reuters
·
14 May

Moleculin Biotech Q1 EPS $(0.69) Beats $(0.83) Estimate

Benzinga
·
14 May

BUZZ-U.S. STOCKS ON THE MOVE-Hims & Hers Health, TXNM Energy, Forge Global

Reuters
·
13 May

Moleculin Biotech’s Annamycin Trial Approved by EMA

TIPRANKS
·
12 May

Moleculin Biotech Cancels Special Stockholders Meeting

TIPRANKS
·
10 May

Moleculin Biotech Inc expected to post a loss of 56 cents a share - Earnings Preview

Reuters
·
06 May

BRIEF-Moleculin Biotech Granted Two Additional U.S. Patents For Annamycin

Reuters
·
05 May